Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
- The report reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Plaque Psoriasis (Psoriasis Vulgaris) therapeutics and enlists all their major and minor projects
- The report assesses Plaque Psoriasis (Psoriasis Vulgaris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAbbVie Inc
Abcentra LLC
Accro Bioscience Suzhou Co Ltd
Acelyrin Inc
Akeso Inc
Aldeyra Therapeutics Inc
Allorion Therapeutics Inc
AltruBio Inc
Alumis Inc
Alvotech SA
Amgen Inc
Arcutis Biotherapeutics Inc
Artax Biopharma Inc
Arxx Therapeutics AS
Aurigene Oncology Ltd
Avesthagen Ltd
Azora Therapeutics Australia Pty Ltd
BCY Pharm Co Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
BioApex sro
Biocad
Biocon Ltd
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
Cantargia AB
Celltrion Inc
Celon Pharma SA
Changzhou Hengbang Pharmaceutical Co Ltd
Cipher Pharmaceuticals Inc
Clonz Biotech Pvt Ltd
Coegin Pharma AB
Crescita Therapeutics Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
Curapel Ltd
DelArrivo Inc
Dermaliq Therapeutics Inc
DICE Therapeutics Inc
DNX Biopharmaceuticals Inc
E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd
Eli Lilly and Co
Eluciderm Inc
Escalier Biosciences BV
Evelo Biosciences Inc
Formycon AG
FunPep Co Ltd
Galapagos NV
Galectin Therapeutics Inc
Gan & Lee Pharmaceuticals Co Ltd
GC Biopharma Corp
GC Cell Corp
Gen Ilac ve Saglik Urunleri AS
Genentech USA Inc
Generium
Genrix (Shanghai) Biopharmaceutical Co Ltd
GSK plc
Hangzhou Highlightll Pharmaceutical Co Ltd
HLK Pharmacin LLC
Huabo Biopharm (Shanghai) Co Ltd
Huaxia Source Cell Engineering Group Co Ltd
InnoCare Pharma Ltd
Innovent Biologics Inc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
KoBioLabs Inc
Leo Pharma AS
Lipidor AB
Livzon Pharmaceutical Group Co Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
Mabscale LLC
MC2 Therapeutics AS
Meiji Seika Pharma Co Ltd
MetrioPharm AG
Minapharm Pharmaceuticals
Minghui Pharmaceutical (Shanghai) Co Ltd
MoonLake Immunotherapeutics
Mycenax Biotech Inc
Nektar Therapeutics
NeuClone Pty Ltd
Newsoara Biopharma Co Ltd
NKGen Biotech Inc
Ono Pharmaceutical Co Ltd
OrchestratePharma GmbH
Orphagen Pharmaceuticals Inc
Pharmapraxis
ProTransit Nanotherapy LLC
Provectus Biopharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Samsung Bioepis Co Ltd
Sandoz Group AG
Sanofi
Sareum Holdings Plc
Scinai Immunotherapeutics Ltd
SFA Therapeutics Inc
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Celgen Bio-Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shilpa Biologicals Pvt Ltd
Ship of Theseus LLC
Siam Bioscience Co Ltd
Simcere Pharmaceutical Group Ltd
Sinopharm Zhongsheng Biotechnology Research Institute Co Ltd
Soligenix Inc
STgen Bio Co Ltd
Sun Pharmaceutical Industries Ltd
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syntrix Pharmaceuticals
Takeda Pharmaceutical Co Ltd
Tianjin Ever Union Biotechnology Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
UCB SA
Union Therapeutics AS
Ventyx Biosciences Inc
Viva Vision Biotech
VYNE Therapeutics Inc
Wuhan Institute of Biological Products Co Ltd
Zai Lab Ltd
Zhejiang Borui Biopharmaceutical Co Ltd